Literature DB >> 2998070

Difference in sensitivity to interferon among mouse hepatitis viruses with high and low virulence for mice.

F Taguchi, S G Siddell.   

Abstract

Mouse hepatitis viruses (MHV) of different virulence for mice were studied with respect to interferon (IFN) sensitivity. The growth of low-virulent MHV-S and intermediately virulent MHV-JHM was significantly suppressed in IFN-treated L cells compared with untreated cells. However, a comparable suppression of the growth of highly virulent MHV-2 was not observed in IFN-treated cells. This differential effect of IFN treatment could also be demonstrated at the level of viral mRNA and viral proteins. In cells infected with MHV-S or MHV-JHM the amount of viral mRNAs was remarkably reduced by IFN treatment. Also the levels of the major intracellular viral proteins, in particular the E1 protein, were affected by IFN treatment. Similar effects could not be demonstrated in MHV-2-infected cells. These results suggest that during MHV-S or MHV-JHM infection IFN treatment suppresses virus replication at several stages. The significance of these results is discussed in terms of the pathogenecity of these viruses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2998070      PMCID: PMC7130510          DOI: 10.1016/0042-6822(85)90225-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  29 in total

1.  Production by mixed lymphocyte cultures of a type II interferon able to protect macrophages against virus infection.

Authors:  J L Virelizier; A C Allison; E de Maeyer
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

2.  Factors involved in the age-dependent resistance of mice infected with low-virulence mouse hepatitis virus.

Authors:  F Taguchi; A Yamada; K Fujiwara
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

3.  Resistance to highly virulent mouse hepatitis virus acquired by mice after low-virulence infection: enhanced antiviral activity of macrophages.

Authors:  F Taguchi; A Yamada; K Fujiwara
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

Review 4.  The biology and pathogenesis of coronaviruses.

Authors:  H Wege; S Siddell; V ter Meulen
Journal:  Curr Top Microbiol Immunol       Date:  1982       Impact factor: 4.291

Review 5.  The biology of coronaviruses.

Authors:  S Siddell; H Wege; V Ter Meulen
Journal:  J Gen Virol       Date:  1983-04       Impact factor: 3.891

6.  Correlation of persistent mouse hepatitis virus (MHV-3) infection with its effect on mouse macrophage cultures.

Authors:  J L Virelizier; A C Allison
Journal:  Arch Virol       Date:  1976       Impact factor: 2.574

7.  Resistance to fatal central nervous system disease by mouse hepatitis virus, strain JHM. II. Adherent cell-mediated protection.

Authors:  S A Stohlman; J A Frelinger; L P Weiner
Journal:  J Immunol       Date:  1980-04       Impact factor: 5.422

8.  Blocking of in vitro and in vivo susceptibility to mouse hepatitis virus.

Authors:  W Y Weiser; F B Bang
Journal:  J Exp Med       Date:  1977-11-01       Impact factor: 14.307

9.  Coronavirus mRNA synthesis involves fusion of non-contiguous sequences.

Authors:  W Spaan; H Delius; M Skinner; J Armstrong; P Rottier; S Smeekens; B A van der Zeijst; S G Siddell
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

10.  The biological relationship of mouse hepatitis virus (MHV) strains and interferon: in vitro induction and sensitivities.

Authors:  L E Garlinghouse; A L Smith; T Holford
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

View more
  14 in total

1.  Intracellular complexes of viral spike and cellular receptor accumulate during cytopathic murine coronavirus infections.

Authors:  P V Rao; T M Gallagher
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

2.  Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice.

Authors:  Nadine De Albuquerque; Ehtesham Baig; Xuezhong Ma; Jianhua Zhang; William He; Andrea Rowe; Marlena Habal; Mingfeng Liu; Itay Shalev; Gregory P Downey; Reginald Gorczynski; Jagdish Butany; Julian Leibowitz; Susan R Weiss; Ian D McGilvray; M James Phillips; Eleanor N Fish; Gary A Levy
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 3.  Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.

Authors:  Susan R Weiss; Sonia Navas-Martin
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

4.  Mouse hepatitis coronavirus A59 nucleocapsid protein is a type I interferon antagonist.

Authors:  Ye Ye; Kevin Hauns; Jeffrey O Langland; Bertram L Jacobs; Brenda G Hogue
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  Accessory protein 5a is a major antagonist of the antiviral action of interferon against murine coronavirus.

Authors:  Cheri A Koetzner; Lili Kuo; Scott J Goebel; Amy B Dean; Monica M Parker; Paul S Masters
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

6.  Murine coronavirus mouse hepatitis virus is recognized by MDA5 and induces type I interferon in brain macrophages/microglia.

Authors:  Jessica K Roth-Cross; Susan J Bender; Susan R Weiss
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

7.  Inhibition of the alpha/beta interferon response by mouse hepatitis virus at multiple levels.

Authors:  Jessica K Roth-Cross; Luis Martínez-Sobrido; Erin P Scott; Adolfo García-Sastre; Susan R Weiss
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

8.  Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane.

Authors:  Matthew Frieman; Boyd Yount; Mark Heise; Sarah A Kopecky-Bromberg; Peter Palese; Ralph S Baric
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

9.  MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.

Authors:  Adriaan H de Wilde; V Stalin Raj; Diede Oudshoorn; Theo M Bestebroer; Stefan van Nieuwkoop; Ronald W A L Limpens; Clara C Posthuma; Yvonne van der Meer; Montserrat Bárcena; Bart L Haagmans; Eric J Snijder; Bernadette G van den Hoogen
Journal:  J Gen Virol       Date:  2013-04-25       Impact factor: 3.891

Review 10.  SARS coronavirus and innate immunity.

Authors:  Matthew Frieman; Mark Heise; Ralph Baric
Journal:  Virus Res       Date:  2007-04-23       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.